Close Menu

IP Update: Dec 31, 2009


Title: Oligoribonucleotide Derivatives for Specific Inhibition of Gene Expression

Patent Number: 7,635,769

Filed: Sept. 22, 2005

Lead Inventor: Eugen Uhlmann, Sanofi-Aventis

The invention, the patent's abstract states, "relates to oligoribonucleotide derivatives [that] have a 2'5'-linked oligoribonucleotide residue without a 5'-phosphate residue on the 3' end, and to the use thereof for specific inhibition of gene expression."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Nature News reports that genomics is being applied to trace and try to prevent additional COVID-19 waves.

Rady's Children Hospital and San Diego County are teaming up to test pediatric patients and their families for COVID-19 to gauge the spread of the virus locally, according to the San Diego Union-Tribune.

Wildlife managers aim to boost the genetic diversity of Mexican gray wolves by placing captive-born foster pups into packs with similarly aged wild pups, the Mercury News reports.

In Science this week: Genetic Probability tool identifies likely diagnoses in 45 percent of inflammatory arthritis cases, and more.